Immunization of LDL receptor-deficient mice with β 2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques

Thrombosis and Haemostasis

Volumn 97, Issue 1, 2007, Pages 129-138

  Dunoyer Geindre, Sylvie ^a   Kwak, Brenda R ^a,b   Pelli, Graziano ^a   Roth, Isabelle ^a   Satta, Nathalie ^a   Fish, Richard J ^a,b   Reber, Guido ^a   Mach, François ^a,b   Kruithof, Egbert K O ^a,b   de Moerloose, Philippe ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

2 glycoprotein 1; Antiphospholipid antibodies; Atherosclerosis; Immunization; Statins

Indexed keywords

BETA ACTIN; BETA2 GLYCOPROTEIN 1; CD4 ANTIGEN; CD68 ANTIGEN; GAMMA INTERFERON; GELATINASE B; HUMAN SERUM ALBUMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPID ANTIBODY; PRAVASTATIN; RIBI; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNIZATION; INFLAMMATORY DISEASE; LIPID ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ATHEROSCLEROSIS; BETA 2-GLYCOPROTEIN I; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNIZATION; INFLAMMATION; ISOANTIBODIES; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; SERUM ALBUMIN;

EID: 33846980145     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-06-0340     Document Type: Article

References (34)

1. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005; 44: 1492-502.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Vaarala O. Auto-antibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Int Med 2000; 247: 381-4.
4. Jara LJ, Medina G, Vera-Lastra O, et al. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 25: 79-88.
5. Nityanand S, Bergmark C, de Faire U, et al. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Int Med 1995; 238: 437-43.
6. Dropinski J, Szczeklik W, Rubis P, et al. Antiphospholipid antibodies and carotid-artery intimamedia thickness in young survivors of myocardial infarction. Med Sci Monit 2003; 9: BRI05-109.
7. George J, Harats D, Gilburd B, et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999: 99: 2227-30.
8. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake bymacrophages. Clin Exp Immunol 1997; 107:569-74.
9. Roubey RA. Tissue factor pathway and the antiphospholipid syndrome. J Autoimmun 2000; 15:217-20.
10. Meroni PL, Raschi E, Testoni C, et al. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004; 112:169-74.
11. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8:1257-62.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
13. George J, Afek A, Gilburd B, et al. Induction of early atherosclerosis in LDL-Receptor -deficient mice immunized with β2-glycoprotein I. Circulation 1998; 98: 1108-15.
14. Afek A, George J, Shoenfeld Y, et al. Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 1999; 67:19-25.
15. Tincani A, Gilburd B, Abu-Shakra M, et al. Immunization of naive BALB/c mice with human β2-glycoprotein I breaks tolerance to the murine molecule. Arthritis Rheum 2002; 46: 1399-404.
16. George J, Harats D, Gilburd B, et al. Adoptive transfer of β2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102: 1822-7.
17. Kwak BR, Mulhaupt F, Mach E Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003; 2: 332-8.
18. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-9.
19. Williams H, Johnson JL, Carson KG, et al. Characteristic of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 788-92.
20. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 1990; 39: 1158-64.
21. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between exes in LDL-receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995; 36: 2320-8.
22. Veillard NR, Steffens S, Burger F, et al. Differential expression pattern of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol 2004; 24: 2339-44.
23. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, et al. NFkappaB is an essential intermediate in the activation of endothelial cells by antibeta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002; 88:851-7.
24. Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341:923-5.
25. Virella G, Atchley DH, Koskinen S, et al. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002; 105: 81-92.
26. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004; 30: 73-80.
27. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 5: 2120-4.
28. Xu Q, Dietrich H, Steiner HJ, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb Vasc Biol 1992; 12: 789-99.
29. Lamb DJ, Eales LJ, Ferns GA. Immunization with Bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 1999; 143: 105-13.
30. Aikawa M, Libby P. Lipid lowering therapy in atherosclerosis. Semin Vasc Med 2004; 4: 357-66.
31. Van de Poll SW, Delsing DJ, Wouter Jukema J, et al. Effect of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaques in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol 2003; 35: 109-18.
32. Kwak BR, Veillard N, Pelli G, et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 2003; 107: 1033-9.
33. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler ThrombVasc Biol 1998; 18: 1671-8.
34. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidermic rabbits. Circulation 2001; 103: 993-9.